Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

301. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. (Full text)

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.  To determine the association between use of sulphonylureas and risk of hypoglycaemia in relation to renal function and sulphonylurea metabolic group compared with use of metformin. Population based cohort study using routinely collected data from general practices in England. Clinical Practice Research Datalink (CPRD) database (...) for age, sex, lifestyle, comorbidity, and drug use. The risk of hypoglycaemia in current users of sulphonylureas only was significantly increased compared with current users of metformin only (adjusted hazard ratio 2.50, 95% confidence interval 2.23 to 2.82). The higher risk in current users of sulphonylureas only was further increased in patients with an estimated glomerular filtration rate of less than 30 mL/min/1.73 m(2) (4.96, 3.76 to 6.55). The risk of hypoglycaemia was also significantly higher

2016 BMJ PubMed abstract

302. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial (Full text)

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients with type 2 diabetes not achieving adequate glycemic control on metformin alone.In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide (...) for lixisenatide; P = 0.23). The most common adverse events in both groups were gastrointestinal disorders. Greater increases in pulse, lipase, and amylase were observed with liraglutide. Hypoglycemic episodes were rare and similar between the two treatments.At the dose levels studied, liraglutide was more effective than lixisenatide as add-on to metformin in improving glycemic control. Body weight reductions were similar. Both treatments were well tolerated, with low risk of hypoglycemia and similar

2016 EvidenceUpdates Controlled trial quality: uncertain PubMed abstract

303. XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes

XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes XIGDUO SUMMARY CT14263

2016 Haute Autorite de sante

304. Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis. (Abstract)

Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis. A growing body of evidence has suggested that metformin potentially reduces the risk of cancer.We performed a meta-analysis of available studies to better define the effect of metformin on colon neoplasia (cancer and polyps) in patients with type 2 diabetes.Medical literature searches for human studies were performed through December 2015, using suitable keywords. Pooled estimates were obtained using fixed or random (...) cohort and 3 case-controls)]. The risk of colon neoplasia was significantly lower among metformin users than controls (non-metformin users) [pooled RRs (95% CI)=0.75 (0.65-0.87), test for overall effect Z=-3.95, p<0.001]. This observation applied separately for colon cancer [0.79 (0.69-0.91), Z=-3.34, p<0.001] and for colon polyps [0.58 (0.42-0.80), Z=-3.30, p<0.001].This meta-analysis shows that the use of metformin in patients with type 2 diabetes is associated with significantly lower risk

2016 European journal of internal medicine

305. Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. (Full text)

Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. Although clozapine is the gold-standard for treatment refractory schizophrenia, it has the worst metabolic profile of all antipsychotics. This is partly mediated by clozapine's impact on glucagon-like peptide (GLP-1). There is an absence of robust evidence for effective treatments for clozapine associated weight gain and metabolic syndrome. Metformin, with its role in increasing GLP-1 may aid weight loss among (...) people on clozapine.We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus. We searched the Cochrane Schizophrenia Group's trial register, Pubmed and Embase, as well as the following Chinese databases: the Chinese Biomedical Literature Service System and China Knowledge Resource Integrated Database. This was supplemented by hand searches of key papers.Eight studies, of which three

2016 PloS one PubMed abstract

306. Metformin as prevention in people taking antipsychotic medication

Metformin as prevention in people taking antipsychotic medication Metformin as prevention in people taking antipsychotic medication – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2016\/06\/whitepills.jpg"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Jun 14 2016 Metformin as prevention in people (...) taking antipsychotic medication By in , , , , Journal reference: Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 2015 Oct;35(5):499-509. Link: Published: October 2015 Evidence cookie says… The effect of metformin on cardiovascular disease in people living without diabetes on long-term antipsychotic medication is unknown

2016 Morsels of Evidence

307. Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide (Full text)

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide Glioblastoma multiforme (GBM) is a CNS (central nervous system) malignancy with a low cure rate. Median time to progression after standard treatment is 7 months and median overall survival is 15 months [1]. Post-treatment vasculogenesis promoted by recruitment of bone marrow derived cells (BMDCs, CD11b

2016 Oncoscience PubMed abstract

308. WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus. (Abstract)

WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus. 26421423 2016 03 31 2019 06 22 1469-493X 9 2015 Sep 30 The Cochrane database of systematic reviews Cochrane Database Syst Rev WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus. CD002966 10.1002/14651858.CD002966.pub4 Saenz Antonio A Centro de Salud Pozuelo 1, INSALUD - Madrid, Emisora s/n, Pozuelo de Alarcón, Madrid, Spain, 28224. Fernandez-Esteban Inmaculada I Mataix Angel A Ausejo Segura Monica M Roqué i Figuls Marta M (...) Moher David D eng Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Review Systematic Review 2015 09 30 England Cochrane Database Syst Rev 100909747 1361-6137 0 Hypoglycemic Agents 9100L32L2N Metformin IM Cochrane Database Syst Rev. 2005;(3):CD002966 16034881 Diabetes Mellitus, Type 2 drug therapy Humans Hypoglycemic Agents therapeutic use Metformin therapeutic use Randomized Controlled Trials as Topic 2015 10 1 6 0 2015 10 1 6 0 2016 4 1 6 0 epublish 26421423 10.1002/14651858.CD002966

2016 The Cochrane database of systematic reviews

309. Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin (Full text)

Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin.In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg (...) with placebo (p < 0.001). The overall AE incidence was 39.8 and 44.4% for canagliflozin and placebo, respectively. Canagliflozin was associated with an increased incidence of genital mycotic infections.Titrated canagliflozin significantly improved HbA1c, FPG, body weight and SBP, and was generally well tolerated over 26 weeks in patients with T2DM as add-on to metformin and sitagliptin.© 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2016 EvidenceUpdates Controlled trial quality: uncertain PubMed abstract

310. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial (Full text)

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial To compare the efficacy and safety of liraglutide versus sitagliptin as add-on to metformin after 26 weeks of treatment in Chinese patients with type 2 diabetes mellitus (T2DM).This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM (...) inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily oral sitagliptin 100 mg (n = 184), both as add-on to metformin. The primary endpoint was change in HbA1c from baseline to week 26.Liraglutide was superior to sitagliptin in reducing HbA1c from baseline [8.1% (65 mmol/mol)] to 26 weeks, as evidenced by estimated mean HbA1c change of -1.65% (-18.07 mmol/mol) versus -0.98

2016 EvidenceUpdates Controlled trial quality: uncertain PubMed abstract

311. Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. (Full text)

Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. Polycystic ovarian syndrome (PCOS) is a common disease. There is limited evidence to support various treatment choices. This leads to variable treatment practices.To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the use of metformin versus oral contraceptive pills (OCPs) for the treatment of PCOS in adolescents aged 11 to 19 years.We performed (...) difference [WMD] = 0.27, P < .01, 95% confidence interval [CI] -0.33 to -0.21) and mild reduction of acne scores (WMD = 0.3, P = .02, 95% CI 0.05 to 0.55). While metformin resulted in greater BMI reduction (WMD = -4.02, P < .01, 95% CI -5.23 to -2.81) it was associated with decreased dysglycemia prevalence (risk ratio: 0.41, P = .02, 95% CI 0.19 to 0.86) and improved total cholesterol and low-density lipoprotein levels. Metformin and OCPs were similar in terms of impact on hirsutism.Current evidence

2016 Pediatrics PubMed abstract

312. Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. (Full text)

Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. The aim of this study was to assess the effects of orlistat on weight loss-related clinical variables in overweight/obese women with polycystic ovary syndrome (PCOS) and to compare treatment with orlistat vs. metformin in this group.We conducted a systematic review and meta-analysis of the evidence about the use of orlistat in women with PCOS. We searched (...) reported an improvement in testosterone levels. Eight studies evaluated impact on insulin resistance, and five reported improvement. Finally, five studies evaluated impact on lipid profile, and four reported improvement. Three randomised control trials were included in the fixed effects model meta-analysis for a total of 121 women with PCOS. Orlistat and metformin had similar positive effects on BMI (-0.65%, 95% CI: -2.03 to 0.73), HOMA (-3.60%, 95% CI: -16.99 to 9.78), testosterone (-2.08%, 95% CI

2016 International journal of clinical practice PubMed abstract

313. A Systematic Review and Network Meta-Analysis Assessing the Effectiveness and Tolerability of Gliptins and Sulfonylureas as Monotherapy in Patients with Type 2 Diabetes Mellitus If Metformin is not Considered Appropriate. (Full text)

A Systematic Review and Network Meta-Analysis Assessing the Effectiveness and Tolerability of Gliptins and Sulfonylureas as Monotherapy in Patients with Type 2 Diabetes Mellitus If Metformin is not Considered Appropriate. 27200582 2016 06 10 2016 05 21 1524-4733 17 7 2014 Nov Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Value Health A Systematic Review and Network Meta-Analysis Assessing the Effectiveness and Tolerability of Gliptins (...) and Sulfonylureas as Monotherapy in Patients with Type 2 Diabetes Mellitus If Metformin is not Considered Appropriate. A333 10.1016/j.jval.2014.08.634 S1098-3015(14)02564-9 Bartmus T T Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, Munich, Germany. Mansmann U U Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, Munich, Germany. eng Journal Article 2014 10 26 United States Value Health

2016 Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research PubMed abstract

314. Metformin for treatment of clozapine-induced weight gain in adult patients with schizophrenia: a meta-analysis. (Full text)

Metformin for treatment of clozapine-induced weight gain in adult patients with schizophrenia: a meta-analysis. Long-term use of clozapine for individuals with schizophrenia carries a high risk for developing metabolic abnormalities, especially clozapine-induced weight gain. Previous studies suggest that metformin can decrease clozapine-induced weight gain, but the sample sizes of most of these studies are relatively small.We identified randomized controlled trials (RCTs) published prior (...) to December 15, 2015 about the use of metformin to treat clozapine-induced weight gain in adults with schizophrenia by searching several English-language and Chinese-language databases. Two independent researchers did the screening and data extraction. We used Revman 5.3 to conduct the meta-analyses, assessed the risk of bias (RoB), and assessed the strength of the evidence using the Cochrane Grades of Recommendation, Assessment, Development, and Evaluation (GRADE).Six studies with a pooled sample of 207

2016 Shanghai archives of psychiatry PubMed abstract

315. Systematic review of metformin use in obese nondiabetic children and adolescents. (Abstract)

Systematic review of metformin use in obese nondiabetic children and adolescents. Childhood obesity has become epidemic and has been accompanied by an increase in prevalence of type 2 diabetes (T2DM) in youth. Addressing obesity and insulin resistance by drug treatment represents a rational strategy for the prevention of T2DM. A systematic review was performed to evaluate the effectiveness of metformin in reducing weight and ameliorating insulin resistance in obese nondiabetic children.A PubMed (...) database search was conducted, using 'metformin', 'obesity', 'insulin resistance', 'children', 'adolescents' as search terms.Eleven trials were included in the present review. Metformin was administered for 6-12 months at a dosage of 1,000-2,000 mg/daily, decreasing BMI by 1.1-2.7 compared with placebo or lifestyle intervention alone. Concomitantly, fasting insulin resistance improved after metformin therapy. Posttreatment follow-up was performed in one study, showing that after 1 year

2016 Hormone research in paediatrics

316. Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis. (Full text)

Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis. Diabetic patients have a higher risk of colorectal cancer (CRC). The role of metformin in CRC incidence among type 2 diabetes mellitus (T2DM) remains controversial.A meta-analysis was performed to evaluate the role of metformin treatment in the occurrence of CRC among T2DM patients.Search was performed throughout PubMed, Embase, Springer databases up to November 2014. The search terms were (...) (biguanides or metformin) and (bowel or colon or rectal or colorectal) and (cancer or neoplasm or neoplasia). Relative risk (RR) and 95% confidence interval (CI) was pooled using random-effects model or fixed-effect model basing on heterogeneity, which was calculated basing on Q statistics and χ2 test. In addition, subgroup analyses were performed according to region, study design and control treatment. Finally, publication bias was evaluated using Egger's regression test and trim and fill analysis.A

2016 Pharmaceutical biology PubMed abstract

317. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. (Abstract)

Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. To assess the short- and long-term maternal and fetal impact of metformin in pregnancy compared with insulin.We performed a comprehensive literature search of MEDLINE, EMBASE, BIOSIS, Cochrane Database of Systematic Reviews and ClinicalTrials.gov. Eligible studies were randomized control trials (RCTs) or follow-up of an RCT that: (1) compared metformin with insulin (...) in pregnancy in women with gestational diabetes mellitus or Type 2 diabetes; and (2) reported maternal or fetal outcomes of interest. Two reviewers extracted the data, evaluated study quality and calculated pooled estimates.Sixteen studies (n = 2165 in quantitative analysis) were included. Metformin lowered the risk of neonatal hypoglycaemia [risk ratio (RR) = 0.63; 95% confidence interval (95% CI), 0.45 to 0.87], large for gestational age babies (RR = 0.80; 95% CI, 0.64 to 0.99), pregnancy-induced

2016 Diabetic medicine : a journal of the British Diabetic Association

318. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: A systematic review and meta-analysis. (Full text)

Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: A systematic review and meta-analysis. Metformin is the most widely used oral hypoglycaemic drug, but it may lower B12 status, which could have important clinical implications. We undertook a systematic review and meta-analysis of the relationship between metformin use and vitamin B12 deficiency in persons with type 2 diabetes.Electronic database searches were undertaken (1st January 1957-1st July 2013 (...) ) using the Cochrane library, Scopus, CINAHL, Grey literature databases, Pub Med Central, NICE Clinical Guidelines UK, and ongoing clinical trials. Included studies were of any study design, with data from patients with type 2 diabetes of any age or gender, taking any dose or duration of metformin. Planned primary outcomes were serum vitamin B12 levels, % prevalence or incidence of vitamin B12 deficiency and risk of vitamin B12 deficiency.Twenty-six papers were included in the review. Ten out of 17

2016 Diabetes & metabolism PubMed abstract

319. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. (Full text)

Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. 27118195 2019 11 20 1460-2369 22 3 2016 04 Human reproduction update Hum. Reprod. Update Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. 408-9 10.1093/humupd/dmv063 dmv063 Naderpoor Negar N Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, 43-51 Kanooka Grove

2016 Human Reproduction Update PubMed abstract

320. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. (Abstract)

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices.To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors (...) , and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes.English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015).Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations.Two reviewers independently assessed study

2016 Annals of Internal Medicine